Inclusion Criteria:

          -  Cytologically or histologically confirmed diagnosis of relapsed/refractory or newly
             diagnosed AML per WHO 2016 classification.

          -  Phase 1a: AML that is relapsed/refractory or that is previously untreated in patients
             not considered suitable for intensive induction therapy.

          -  Phase 1b: AML that is relapsed/refractory after prior treatment with a HMA-based
             regimen.

          -  Phase 2: Previously untreated AML in patients who are not considered suitable
             candidates for intensive induction therapy.

          -  Adequate renal and liver function.

          -  Age ≥18 years.

          -  Adequate performance status.

        Exclusion Criteria:

          -  In Phase 1a and 1b, patients that have undergone prior allo-HSCT must be at least 3
             months post-HSCT, without uncontrolled graft-versus-host disease (GVHD). For Phase 2,
             patients that have undergone prior allo-HSCT are excluded.

          -  Patients with newly diagnosed AML with favorable risk cytogenetics such as t(8;21),
             inv(16), or t(16;16) as per the NCCN Guidelines Version 3, 2019 for AML.

          -  Patients with acute promyelocytic leukemia (APL).

          -  Prior treatment with any anti-CD47 or anti-SIRPalpha (signal regulatory protein alpha)
             agent.

          -  Known active viral infections, including hepatitis B and C, human immunodeficiency
             virus (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or SARS-CoV-2
             (severe acute respiratory syndrome coronavirus 2).